You are here: Industry Insights > Market News > Moderna signs supply pact with Argentina for 20 million doses of its COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Moderna signs supply pact with Argentina for 20 million doses of its COVID-19 vaccine

expresspharmaJuly 13, 2021

Tag: Moderna , Argentina , COVID-19 Vaccine

Favorites

Moderna announced a supply agreement with the government of Argentina for 20 million doses of Moderna’s COVID-19 vaccine or its updated variant booster vaccine candidate, if authorised, to begin delivery in the first quarter of 2022.

Moderna signs supply pact with Argentina for 20 million doses of its COVID-19 vaccine

“We appreciate the support from the government of Argentina with this supply agreement for doses of the Moderna COVID-19 vaccine or our variant booster candidates,” said Stéphane Bancel, Chief Executive Officer of Moderna. “

Previous:Schneider Electric and Kewaunee International announce strategic alliance to create next-gen labs

Next:SINOVAC signs agreement to supply CoronaVac to COVAX

Vetter Wins Best Managed Companies Award 2024

Biotech NewswireMay 30, 2024

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

Biotech NewswireMay 30, 2024

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Moderna signs supply pact with Argentina for 20 million doses of its COVID-19 vaccine | Pharmasources.com

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Moderna signs supply pact with Argentina for 20 million doses of its COVID-19 vaccine

Related News

Vetter Wins Best Managed Companies Award 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

You may like